Amylyx Pharmaceuticals Inc (NAS:AMLX)
$ 3.87 -0.2 (-4.91%) Market Cap: 265.28 Mil Enterprise Value: 33.45 Mil PE Ratio: 0 PB Ratio: 1.35 GF Score: 21/100

Amylyx Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Nov 29, 2022 / 08:05PM GMT
Release Date Price: $37 (+0.95%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Thank you guys for joining us. It's a pleasure to have Amylyx management join us. There's a lot to discuss. And I'm looking forward to the discussion, but let me first turn it over to you guys, if you want to kick it off.

Unidentified Company Representative

Yes. Very happy to -- well, first of all, thanks so much for having us and really excited to get to share with you all. So Justin, Josh, Jim, so the management team here at Amylyx. Amylyx is focused in ending the suffering caused by neurodegenerative diseases. And I think particularly, things are focused right now around RELYVRIO in the U.S., ALBRIOZA in Canada, which is our newly approved treatment for ALS. So this is an exciting time for us. The FDA approval is just September 29. And our team is hard at work, focused on making sure that we deliver for a community that really needs us. The main things right now are everything you would expect at launch, although it's just the early weeks now.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot